Scienza e Tecnologia
DelveInsight Estimates a Promising Picture of JAK Inhibitors Clinical Trial Pipeline Landscape in the Coming Years as 40+ Key Pharma Players Bolster the Treatment Space
Request a sample and discover the recent advances in the JAK inhibitors market @
Janus kinase (JAK) inhibitors are small molecules of about 400 Da that can be administered orally. JAKs are phosphotransferases that bind to cytokine receptor intracellular domains and transmit signals to activate immune responses. Many interleukins, interferons, colony-stimulating factors, and hormone-like cytokines are among the cytokines that signal via JAKs (such as erythropoietin). These cytokine receptors communicate via various combinations of four JAKs (JAK1, JAK2, JAK3, and TYK2).
Tofacitinib and baricitinib (and oclacitinib in dogs) are first-generation jakinibs that block more than one JAK and thus inhibit many cytokines; these and other pan-jakinibs are being studied as therapeutic agents for a wide range of autoimmune diseases.
Several JAK inhibitor clinical trials are currently underway, ranging from cancer to autoimmune diseases like psoriasis. Several other JAK inhibitors may be effective in the treatment of multiple disorders in the future.
Find out more about FDA JAK inhibitors @
RINVOQ, a selective JAK inhibitor discovered and developed by AbbVie scientists, is being studied in a variety of immune-mediated inflammatory diseases. RINVOQ inhibited JAK-1 more effectively than JAK-2, JAK-3, and TYK-2 in enzymatic and cellular assays. The importance of inhibiting specific JAK enzymes to therapeutic efficacy and safety is unknown at this time.
RINVOQ is currently being studied in phase III trials for colitis, giant cell arteritis, and Takayasu arteritis.
Galapagos' Filgotinib (200 mg and 100 mg tablets) is approved and marketed in Europe and Japan for the treatment of adults with moderately to severely active RA who have not responded adequately or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Filgotinib can be used alone or in conjunction with methotrexate (MTX). Filgotinib was submitted to the European Commission for an expanded indication for the treatment of adults with moderate to severe active ulcerative colitis who had an inadequate response, lost response to, or were intolerant to, conventional therapy or a biologic agent.
Learn more about the JAK inhibitor drugs @
Dive deep for rich insights into JAK inhibitor therapy; visit @
For further information on the JAK inhibitors therapeutics assessment, reach out @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key graft vs. host disease companies including among others.
report delivers an in-depth understanding of the disease, historical and forecasted graft vs. host disease epidemiology in the 7MM, i.e., the United States , EU5 ( Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key graft vs. host disease companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myelofibrosis companies including among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/delveinsight-estimates-a-promising-picture-of-jak-inhibitors-clinical-trial-pipeline-landscape-in-the-coming-years-as-40-key-pharma-players-bolster-the-treatment-space-301678000.html